title: Eradication of Helicobacter pylori: recent advances in treatment.
abstract: Helicobacter pylori plays a key role in dyspepsia, peptic ulcer disease, and gastric neoplasia and eradication of the infection has become an important treatment goal in clinical practice. Seven-day proton-pump inhibitor-amoxicillin-clarithromycin triple therapy is the current first-line therapy for H. pylori but eradication rates are compromised by poor compliance and antibiotic resistance. Ten-day sequential treatment may emerge as an alternative first-line therapy. Bismuth-based quadruple therapy is the second-line regimen of choice. Antimicrobial sensitivity testing is not recommended in the routine management of H. pylori infection. Novel triple-therapy regimens containing rifabutin, levofloxacin, or furazolidone may be useful alternatives as second- or third-line therapy.
authors: Department of Gastroenterology, Adelaide and Meath Hospital, Tallaght, Dublin 24 and Faculty of Health Sciences, Trinity College, Dublin, Ireland.
authors: Ramona M
authors: RM
authors: McLoughlin
authors: Colm A
authors: CA
authors: O'Morain
authors: Humphrey J
authors: HJ
authors: O'Connor
mesh_terms: D024881:Drug Resistance, Bacterial; D005664:Furazolidone / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000627:therapeutic use; D010349:Patient Compliance; D017828:Rifabutin / Q000627:therapeutic use; D013997:Time Factors; D017211:Treatment Failure
chemical_list: D017828:Rifabutin; D005664:Furazolidone; D064704:Levofloxacin; D015242:Ofloxacin